1LB Development and validation of robust immunohistochemical assays for phospho-histone-H3 and Eg5 as pharmacodynamic biomarkers to support Eg5 inhibitor (LY2523355) clinical trials in patients with advanced malignancies

A. Nasir, R.D. Van Horn, B. Domazet, X.S. Ye, K.M. Credille, A. Kyshtoobayeva, J.T. Brandt, E.H. Westin, A.E. McGlothlin, T.R. Holzer. Eli Lilly and Co., Diagnostic and Experimental Medicine, Indianapolis IN, USA; Eli Lilly and Co., Lilly Research Labs, Indianapolis IN, USA; Clarient, Immunopathology, Aliso Viejo CA, USA; Eli Lilly and Co., Oncology Business Unit, Indianapolis IN, USA; Eli Lilly and Co., Statistics, Indianapolis IN, USA